Phase 2/3Enrolling by invitation
Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM (FOREST-HCM)
A Follow-Up, Open-Label, Research Evaluation of Sustained Treatment With Aficamten (CK-3773274) in Hypertrophic Cardiomyopathy (HCM)
- Sponsor
- Cytokinetics (Industry)
- Enrolment
- 900 planned
- Conditions
- Symptomatic Hypertrophic Cardiomyopathy (HCM)
- Interventions
- Aficamten (5 - 20 mg)
- Ages
- adults, older adults
- Registry
- NCT04848506, CTIS2023-508963-58-00, EUCTR2020-003571-17
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to collect long-term safety and tolerability data for aficamten.
Primary outcomes
- Incidence of adverse events observed during dosing of aficamten in patients with HCM
- Incidence of serious adverse events observed during dosing of aficamten in patients with HCM
- Incidence of left ventricular ejection fraction (LVEF) < 50% observed during dosing of aficamten in patients with HCM
History
Primary completion expected
Last registry update
Started
Registered